In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

UCB gets rights to some cardio/metabolic drugs from Novartis

Executive Summary

UCB Group received German commercialization rights to Novartis's Dafiro (valsartan/amlodipine) and Dafiro HCT (valsartan/amlodipine/hydrochlorothiazide) for hypertension, and will co-promote the diabetes medications Jalra (vildagliptin), and Icandra (vildagliptin/metformin) in the same area.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing-Licensing

Related Companies